Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Titel:
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Auteur:
Stupp, Roger Hegi, Monika E Gorlia, Thierry Erridge, Sara C Perry, James Hong, Yong-Kil Aldape, Kenneth D Lhermitte, Benoit Pietsch, Torsten Grujicic, Danica Steinbach, Joachim Peter Wick, Wolfgang Tarnawski, Rafał Nam, Do-Hyun Hau, Peter Weyerbrock, Astrid Taphoorn, Martin J B Shen, Chiung-Chyi Rao, Nalini Thurzo, László Herrlinger, Ulrich Gupta, Tejpal Kortmann, Rolf-Dieter Adamska, Krystyna McBain, Catherine Brandes, Alba A Tonn, Joerg Christian Schnell, Oliver Wiegel, Thomas Kim, Chae-Yong Nabors, Louis Burt Reardon, David A van den Bent, Martin J Hicking, Christine Markivskyy, Andriy Picard, Martin Weller, Michael